PURPOSE: Symptom control and improved quality of life (QOL) are primary goals of treatment in palliative oncology. The present study assessed and compared patient demographics, baseline Karnofsky Performance Status (KPS) and QOL using the QLQ-C15-PAL questionnaire prior to palliative radiotherapy (RT) for bone, brain, or lung disease. Few studies have used this questionnaire, an abbreviated version that was developed by the European Organization for Research and Treatment of Cancer specifically for patients with advanced cancer to decrease the burden of completing the longer, more time-consuming QLQ-C30. METHODS: Patients referred to an outpatient palliative RT clinic completed QLQ-C15-PAL questionnaires prior to palliative RT for bone, brain, or lung cancer sites. The associations between baseline QLQ-C15-PAL functional/symptom scales, patient demographics, and clinical variables including KPS were explored. RESULTS: When data from all 369 patients were analyzed, higher KPS scores correlated significantly with better overall QOL and higher physical and emotional functioning. The QLQ-C15-PAL provided more detailed information regarding how symptom burden varied depending on disease site. Patients with bone metastases had worse QLQ-C15-PAL scores for pain, while those with brain and lung disease had worse scores for fatigue. Other health-related QOL scores measured by the QLQ-C15-PAL varied as a function of age and gender. CONCLUSION: As the QLQ-C15-PAL provides detailed and often critical information regarding symptom burden, it may eventually be recognized as a universal core questionnaire to assess QOL in this patient population with advanced cancer while relieving the survey burden.
PURPOSE: Symptom control and improved quality of life (QOL) are primary goals of treatment in palliative oncology. The present study assessed and compared patient demographics, baseline Karnofsky Performance Status (KPS) and QOL using the QLQ-C15-PAL questionnaire prior to palliative radiotherapy (RT) for bone, brain, or lung disease. Few studies have used this questionnaire, an abbreviated version that was developed by the European Organization for Research and Treatment of Cancer specifically for patients with advanced cancer to decrease the burden of completing the longer, more time-consuming QLQ-C30. METHODS:Patients referred to an outpatient palliative RT clinic completed QLQ-C15-PAL questionnaires prior to palliative RT for bone, brain, or lung cancer sites. The associations between baseline QLQ-C15-PAL functional/symptom scales, patient demographics, and clinical variables including KPS were explored. RESULTS: When data from all 369 patients were analyzed, higher KPS scores correlated significantly with better overall QOL and higher physical and emotional functioning. The QLQ-C15-PAL provided more detailed information regarding how symptom burden varied depending on disease site. Patients with bone metastases had worse QLQ-C15-PAL scores for pain, while those with brain and lung disease had worse scores for fatigue. Other health-related QOL scores measured by the QLQ-C15-PAL varied as a function of age and gender. CONCLUSION: As the QLQ-C15-PAL provides detailed and often critical information regarding symptom burden, it may eventually be recognized as a universal core questionnaire to assess QOL in this patient population with advanced cancer while relieving the survey burden.
Authors: J A Kramer; D Curran; M Piccart; J C de Haes; P Bruning; J Klijn; I Van Hoorebeeck; R Paridaens Journal: Eur J Cancer Date: 2000-08 Impact factor: 9.162
Authors: G E Gerrard; R J Prestwich; A Edwards; L J Russon; F Richards; C F Johnston; M C Kwok-Williams Journal: Clin Oncol (R Coll Radiol) Date: 2003-10 Impact factor: 4.126
Authors: Michael A Echteld; Luc Deliens; Bregje Onwuteaka-Philipsen; Martin Klein; Gerrit van der Wal Journal: Palliat Med Date: 2006-01 Impact factor: 4.762
Authors: Edward Chow; Amanda Hird; Galina Velikova; Colin Johnson; Linda Dewolf; Andrea Bezjak; Jackson Wu; Jesmin Shafiq; Orhan Sezer; Dimitrios Kardamakis; Yvette van der Linden; Brigette Ma; Monica Castro; Palmira Foro Arnalot; Sam Ahmedzai; Mark Clemons; Peter Hoskin; Albert Yee; Michael Brundage; Andrew Bottomley Journal: Eur J Cancer Date: 2008-12-25 Impact factor: 9.162
Authors: Edward Chow; Jackson S Y Wu; Peter Hoskin; Lawrence R Coia; Soren M Bentzen; Peter H Blitzer Journal: Radiother Oncol Date: 2002-09 Impact factor: 6.280
Authors: N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506
Authors: Murielle E L Mauer; Martin J B Taphoorn; Andrew Bottomley; Corneel Coens; Fabio Efficace; Marc Sanson; Alba A Brandes; Carin C D van der Rijt; Hans J J A Bernsen; Marc Frénay; Cees C Tijssen; Denis Lacombe; Martin J van den Bent Journal: J Clin Oncol Date: 2007-12-20 Impact factor: 44.544
Authors: Leslye Rojas-Concha; Maiken Bang Hansen; Morten Aagaard Petersen; Mogens Groenvold Journal: Support Care Cancer Date: 2019-07-11 Impact factor: 3.603
Authors: Juan Ignacio Arraras; Fernando Arias de la Vega; Gemma Asin; Mikel Rico; Uxue Zarandona; Clara Eito; Koldo Cambra; Marta Barrondo; Marta Errasti; Juan Verdún; Jose Rivadeneira; Miguel Angel Dominguez Journal: Qual Life Res Date: 2013-09-04 Impact factor: 4.147